biostudies-literatureUnknown13Favalli ARegione LombardiaMinistero della SaluteFondazione Romeo ed Enrica InvernizziCOVID-19 has proven to be particularly serious and life-threatening for patients presenting with pre-existing pathologies. Patients affected by rheumatic musculoskeletal disease (RMD) are likely to have impaired immune responses against SARS-CoV-2 infection due to their compromised immune system and the prolonged use of disease-modifying anti-rheumatic drugs (DMARDs), which include conventional synthetic (cs) DMARDs or biologic and targeted synthetic (b/ts) DMARDs. To provide an integrated analysis of the immune response following SARS-CoV-2 infection in RMD patients treated with different classes of DMARDs we carried out an immunological analysis of the antibody responses toward SARS-CoV-2 nucleocapsid and RBD proteins and an extensive immunophenotypic analysis of the major immune cell poFrontiers in immunology873195https://www.ebi.ac.uk/biostudies/studies/S-EPMC9226581biostudies-literatureImmunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.PMC9226581Favalli EGFabbris TPesce EGobbini ACaporali RMaioli GGranucci FBandera AFavalli ASarnicola MLDe Francesco RDonnici LGori AGrifantini RMartinovic MGruarin PNotarbartolo SManganaro LCurti SBiggioggero MMarongiu LAbrignani SZagato EBevilacqua VBombaci MCrosti MMarchisio EfalseImmunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.COVID-19 has proven to be particularly serious and life-threatening for patients presenting with pre-existing pathologies. Patients affected by rheumatic musculoskeletal disease (RMD) are likely to have impaired immune responses against SARS-CoV-2 infection due to their compromised immune system and the prolonged use of disease-modifying anti-rheumatic drugs (DMARDs), which include conventional synthetic (cs) DMARDs or biologic and targeted synthetic (b/ts) DMARDs. To provide an integrated analysis of the immune response following SARS-CoV-2 infection in RMD patients treated with different classes of DMARDs we carried out an immunological analysis of the antibody responses toward SARS-CoV-2 nucleocapsid and RBD proteins and an extensive immunophenotypic analysis of the major immune cell po2022-01-01T00:00:00Z20222026-05-27T20:19:28.973Z2024-11-15T12:44:29.064ZS-EPMC92265813575769910.3389/fimmu.2022.873195